Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus LOSARTAN POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus LOSARTAN POTASSIUM.
BENICAR HCT vs LOSARTAN POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Angiotensin II receptor antagonist. Blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, resulting in vasodilation and reduced aldosterone secretion.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal elimination half-life: losartan ~2 hours; active metabolite E-3174 ~6-9 hours. Clinically, the long half-life of E-3174 allows once-daily dosing.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Losartan and its active metabolite E-3174 are eliminated via renal (35% of dose) and biliary/fecal (60% of dose) routes. Approximately 4% of an oral dose is excreted unchanged in urine, while 6% is excreted as E-3174 in urine.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB